Pharmaceutical pricing is opaque for a reason and increased transparency may not be a benefit, said the speakers during the "Drug Pricing: Manufacturer, Payer, Prescriber, and Patient Perspectives" session at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo in San Diego, April 7-10.
Pharmaceutical pricing is opaque for a reason, said the speakers during the “Drug Pricing: Manufacturer, Payer, Prescriber, and Patient Perspectives” session at the Academy of Managed Care Pharmacy’s 27th Annual Meeting & Expo in San Diego, April 7-10.
What drives the prices of drugs is not the cost of developing the product, but the number of competitors on the market, explained Jeffrey Moe, PhD, executive in residence and adjunct associate professor at the Fuqua School of Business at Duke University.
“Pricing in pharmaceutical is not cost plus,” he said. “It’s value-based pricing which is used in pharmaceuticals.”
Both he and the session’s other speaker, Howard Tag, JD, chief executive officer of Tag & Associates, Inc, agreed that increased transparency could actually be a bad thing. If one party has to reveal what it is willing to negotiate, it can actually bring prices up.
“The sad truth of the economic theory is that with more price transparency … it might defeat my willingness to give you a very low price as long as I know other parties with whom I’m negotiating don’t know I gave you that very low price,” Dr Moe explained.
Mr Tag spent the majority of his part of the session explaining various pricing sources. Between manufacturers, the government, private entities, and negotiations, there are 20 different prices to understand, monitor, and consider when changing payment policies, he said.
The benchmark prices being used are: average wholesale price, wholesale acquisition cost (WAC), average sales price (ASP), average manufacturer price, best prices, estimated acquisition cost, federal upper limit, and state maximum allowable cost.
The 2 that are most often used by Medicare, Medicaid, and private insurers are WAC and ASP, but there are problems with both, according to Mr Tag.
He ended his talk with the open ended question of what will happen when the first $1 million drug hits the market.
“There is by the way a million dollar drug that is ready for release in the EU,” he said. “And it will be coming to the United States in the not-too-distant future.”
The Pivotal Role of Payers in Improving Health Equity, Maternal Health Care in the US
March 26th 2024A presentation at the Greater Philadelphia Business Coalition on Health's 2024 Women’s Health Summit discussed how payers, including employers and public entities, can strategically influence health care purchasing to prioritize maternal health and equity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study
March 19th 2024Based on the findings, investigators acknowledged the critical need to consider racial differences when assessing patients with hidradenitis suppurativa. Health care providers should be vigilant in addressing cardiovascular risk factors in this population, recognizing and addressing racial disparities that may impact disease management.
Read More